Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
PharmaCompass finds 500 drugs with ‘no patents and no competition’ in the FDA Orange Book
In April last year, PharmaCompass
had shared a list of over 300
different dosage forms of drugs whic
Drugs with no patents and no competition – here’s our list of new ‘price-gouging’ targets
Drug price increases have emerged as a core strategy for generic pharmaceutical companies in the rec
Making a fortune out of decades-old prescription drugs
The
importance of taking the right decision in product selection, by the senior
management at pharma
